Skip to main content

Advertisement

SpringerLink
Log in

Recurrent Cellulitis: Risk Factors, Etiology, Pathogenesis and Treatment

  • Skin, Soft Tissue, Bone and Joint Infectious Diseases (N Safdar, Section Editor)
  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Erysipelas and uncomplicated cellulitis are common infections that tend to recur in a substantial proportion of affected patients following an initial episode, especially if the predisposing condition is chronic lymphedema. All patients who suffer an episode of cellulitis should be carefully evaluated to establish the risk of recurrence. Several predisposing conditions (such as lymphedema and skin conditions that serve as a portal of entry for bacteria) can be effectively treated in order to reduce the risk of relapse. The medical literature provides convincing evidence that antimicrobial prophylaxis can markedly reduce the frequency of relapse of erysipelas. Two recent studies performed by the ‘Prophylactic Antibiotics for the Treatment of Cellulitis at Home’ (PATCH) group have clearly confirmed the efficacy of antimicrobial prophylaxis. Penicillin remains the drug of choice. Treatment options in patients with penicillin allergy are limited by the rising prevalence of macrolide resistance among group A streptococci. Further research is required to clarify the optimal penicillin regimen as well as to develop new therapies for patients with allergy to penicillin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Thomas K, Crook A, Foster K, et al. Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: results of the UK Dermatology Clinical Trials Network's PATCH II trial. Br J Dermatol. 2012;166(1):169–78. This was a randomized, double-blind, controlled trial evaluating the efficacy of prophylactic oral penicillin for prevention of recurrent cellulitis. In this trial, penicillin reduced the rate of recurrent celulitis but the result failed to achieve statistical significance.

    Article  CAS  PubMed  Google Scholar 

  2. Thomas KS, Crook AM, Nunn AJ, et al. Penicillin to prevent recurrent leg cellulitis. N Engl J Med. 2013;368(18):1695–703. This was a randomized, double-blind, controlled trial evaluating the efficacy of prophylactic oral penicillin for prevention of recurrent cellulitis in patients with two or more episodes of cellulitis. In this trial, penicillin significantly reduced the rate of recurrence but the protective effect was lost several months after the end of prophylaxis.

    Article  CAS  PubMed  Google Scholar 

  3. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41(10):1373–406.

    Article  PubMed  Google Scholar 

  4. Elston DM. Epidemiology and prevention of skin and soft tissue infections. Cutis. 2004;73(5 Suppl):3–7.

    PubMed  Google Scholar 

  5. Hirschmann JV. Antimicrobial prophylaxis in dermatology. Semin Cutan Med Surg. 2000;19(1):2–9.

    Article  CAS  PubMed  Google Scholar 

  6. Osmon DR. Antimicrobial prophylaxis in adults. Mayo Clin Proc. 2000;75(1):98–109.

    Article  CAS  PubMed  Google Scholar 

  7. Swartz MN, Pasternack MS. Cellulitis and sucutaneous tissue infections. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 6th ed. Philadelphia: Elsevier; 2005. p. 1172–94.

    Google Scholar 

  8. Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med. 2008;168(14):1585–91.

    Article  PubMed  Google Scholar 

  9. Stulberg DL, Penrod MA, Blatny RA. Common bacterial skin infections. Am Fam Physician. 2002;66(1):119–24.

    PubMed  Google Scholar 

  10. Madsen ST. Scarlet fever and erysipelas in Norway during the last hundred years. Infection. 1973;1(2):76–81.

    Article  CAS  PubMed  Google Scholar 

  11. Bartholomeeusen S, Vandenbroucke J, Truyers C, Buntinx F. Epidemiology and comorbidity of erysipelas in primary care. Dermatology. 2007;215(2):118–22.

    Article  PubMed  Google Scholar 

  12. Eriksson B, Jorup-Ronstrom C, Karkkonen K, et al. Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clin Infect Dis. 1996;23(5):1091–8.

    Article  CAS  PubMed  Google Scholar 

  13. Pavlotsky F, Amrani S, Trau H. Recurrent erysipelas: risk factors. J Dtsch Dermatol Ges. 2004;2(2):89–95.

    Article  PubMed  Google Scholar 

  14. Jorup-Ronstrom C, Britton S. Recurrent erysipelas: predisposing factors and costs of prophylaxis. Infection. 1987;15(2):105–6.

    Article  CAS  PubMed  Google Scholar 

  15. Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ. 1999;318(7198):1591–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Stoberl C. The importance of local factors in recurrent erysipelas. Z Hautkr. 1985;60(9):712. 715–718, 721–713.

    CAS  PubMed  Google Scholar 

  17. de Godoy JM, de Godoy MF, Valente A, et al. Lymphoscintigraphic evaluation in patients after erysipelas. Lymphology. 2000;33(4):177–80.

    PubMed  Google Scholar 

  18. Smith RD, Spittell JA, Schirger A. Secondary lymphedema of the leg: its characteristics and diagnostic implications. JAMA. 1963;185:80–2.

    Article  CAS  PubMed  Google Scholar 

  19. Dreyer G, Noroes J, Figueredo-Silva J, Piessens WF. Pathogenesis of lymphatic disease in bancroftian filariasis: a clinical perspective. Parasitol Today. 2000;16(12):544–8.

    Article  CAS  PubMed  Google Scholar 

  20. Mallon E, Powell S, Mortimer P, Ryan TJ. Evidence for altered cell-mediated immunity in postmastectomy lymphoedema. Br J Dermatol. 1997;137(6):928–33.

    Article  CAS  PubMed  Google Scholar 

  21. Bjornsdottir S, Gottfredsson M, Thorisdottir AS, et al. Risk factors for acute cellulitis of the lower limb: a prospective case-control study. Clin Infect Dis. 2005;41(10):1416–22.

    Article  PubMed  Google Scholar 

  22. Roujeau JC, Sigurgeirsson B, Korting HC, et al. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology. 2004;209(4):301–7.

    Article  PubMed  Google Scholar 

  23. Mokni M, Dupuy A, Denguezli M, et al. Risk factors for erysipelas of the leg in Tunisia: a multicenter case-control study. Dermatology. 2006;212(2):108–12.

    Article  PubMed  Google Scholar 

  24. Cox NH. Oedema as a risk factor for multiple episodes of cellulitis/erysipelas of the lower leg: a series with community follow-up. Br J Dermatol. 2006;155(5):947–50.

    Article  CAS  PubMed  Google Scholar 

  25. Dan M, Heller K, Shapira I, et al. Incidence of erysipelas following venectomy for coronary artery bypass surgery. Infection. 1987;15(2):107–8.

    Article  CAS  PubMed  Google Scholar 

  26. Baddour LM, Bisno AL. Recurrent cellulitis after saphenous venectomy for coronary bypass surgery. Ann Intern Med. 1982;97(4):493–6.

    Article  CAS  PubMed  Google Scholar 

  27. Simon MS, Cody RL. Cellulitis after axillary lymph node dissection for carcinoma of the breast. Am J Med. 1992;93(5):543–8.

    Article  CAS  PubMed  Google Scholar 

  28. Baddour LM. Breast cellulitis complicating breast conservation therapy. J Intern Med. 1999;245(1):5–9.

    Article  CAS  PubMed  Google Scholar 

  29. Bouma J, Dankert J. Recurrent acute leg cellulitis in patients after radical vulvectomy. Gynecol Oncol. 1988;29(1):50–7.

    Article  CAS  PubMed  Google Scholar 

  30. Dankert J, Bouma J. Recurrent acute leg cellulitis after hysterectomy with pelvic lymphadenectomy. Br J Obstet Gynaecol. 1987;94(8):788–90.

    Article  CAS  PubMed  Google Scholar 

  31. Lewis SD, Peter GS, Gomez-Marin O, Bisno AL. Risk factors for recurrent lower extremity cellulitis in a U.S. Veterans Medical Center population. Am J Med Sci. 2006;332(6):304–7.

    Article  PubMed  Google Scholar 

  32. McNamara DR, Tleyjeh IM, Berbari EF, et al. A predictive model of recurrent lower extremity cellulitis in a population-based cohort. Arch Intern Med. 2007;167(7):709–15.

    Article  PubMed  Google Scholar 

  33. Karppelin M, Siljander T, Vuopio-Varkila J, et al. Factors predisposing to acute and recurrent bacterial non-necrotizing cellulitis in hospitalized patients: a prospective case-control study. Clin Microbiol Infect. 2010;16(6):729–34.

    Article  CAS  PubMed  Google Scholar 

  34. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666–74.

    Article  CAS  PubMed  Google Scholar 

  35. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46 Suppl 5:S368–77.

    Article  CAS  PubMed  Google Scholar 

  36. Forcade NA, Parchman ML, Jorgensen JH, et al. Prevalence, severity, and treatment of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) skin and soft tissue infections in 10 medical clinics in Texas: a South Texas Ambulatory Research Network (STARNet) study. J Am Board Fam Med. 2011;24(5):543–50.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Oh CC, Ko HC, Lee HY, et al. Antibiotic prophylaxis for preventing recurrent cellulitis: A systematic review and meta-analysis. J Infect. 2014;69(1):26–34. This was a metaanalysis of five randomized, controlled trials evaluating antimicrobial prophylaxis for prevention of recurrent cellulitis. The results strongly sugest that such intervention is both safe and effective.

    Article  PubMed  Google Scholar 

  38. Chakroun M, Ben RF, Battikh R, et al. Benzathine penicillin prophylaxis in recurrent erysipelas. Med Mal Infect. 1994;24(10):894–7.

    Article  Google Scholar 

  39. Kremer M, Zuckerman R, Avraham Z, Raz R. Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections. J Infect. 1991;22(1):37–40.

    Article  CAS  PubMed  Google Scholar 

  40. Sjoblom AC, Eriksson B, Jorup-Ronstrom C, et al. Antibiotic prophylaxis in recurrent erysipelas. Infection. 1993;21(6):390–3.

    Article  CAS  PubMed  Google Scholar 

  41. Hartel S, Gramatte T, Scholz A, Terhaag B. Long-term preventive use of sulfamerazine in chronic recurrent erysipelas. Dermatol Monatsschr. 1988;174(8):485–92.

    CAS  PubMed  Google Scholar 

  42. Babb RR, Spittell Jr JA, Martin WJ, Schirger A. Prophylaxis of recurrent lymphangitis complicating lymphedema. JAMA. 1966;195(10):871–3.

    Article  CAS  PubMed  Google Scholar 

  43. Olszewski WL. Episodic dermatolymphangioadenitis (DLA) in patients with lymphedema of the lower extremities before and after administration of benzathine penicillin: a preliminary study. Lymphology. 1996;29(3):126–31.

    CAS  PubMed  Google Scholar 

  44. Allard P, Stucker M, von Kobyletzki G, et al. Cyclical intravenous antibiosis as an effective therapy concept in chronic recurrent erysipelas. Hautarzt. 1999;50(1):34–8.

    Article  CAS  PubMed  Google Scholar 

  45. Duvanel T, Merot Y, Harms M, Saurat JH. Prophylactic antibiotics in erysipelas. Lancet. 1985;1(8442):1401.

    Article  CAS  PubMed  Google Scholar 

  46. Ziebart-Schroth A. Therapy and prophylaxis of recurrent erysipelas (author's transl). Med Klin. 1976;71:1197–9.

    CAS  PubMed  Google Scholar 

  47. Bergkvist PI, Sjobeck K. Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebo-controlled study. Scand J Infect Dis. 1997;29(4):377–82.

    Article  CAS  PubMed  Google Scholar 

  48. Kasseroller R. Sodium selenite as prophylaxis against erysipelas in secondary lymphedema. Anticancer Res. 1998;18(3C):2227–30.

    CAS  PubMed  Google Scholar 

  49. Leclerc S, Teixeira A, Mahe E, et al. Recurrent erysipelas: 47 cases. Dermatology. 2007;214(1):52–7.

    Article  CAS  PubMed  Google Scholar 

  50. Olszewski WL, Jamal S, Manokaran G, et al. The effectiveness of long-acting penicillin (penidur) in preventing recurrences of dermatolymphangioadenitis (DLA) and controlling skin, deep tissues, and lymph bacterial flora in patients with "filarial" lymphedema. Lymphology. 2005;38(2):66–80.

    CAS  PubMed  Google Scholar 

  51. Vignes S, Dupuy A. Recurrence of lymphoedema-associated cellulitis (erysipelas) under prophylactic antibiotherapy: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2006;20(7):818–22.

    CAS  PubMed  Google Scholar 

  52. Koster JB, Kullberg BJ, van der Meer JW. Recurrent erysipelas despite antibiotic prophylaxis: an analysis from case studies. Neth J Med. 2007;65(3):89–94.

    CAS  PubMed  Google Scholar 

  53. Sjoblom AC, Bruchfeld J, Eriksson B, et al. Skin concentrations of phenoxymethylpenicillin in patients with erysipelas. Infection. 1992;20(1):30–3.

    Article  CAS  PubMed  Google Scholar 

  54. Garcia LB, Benchetrit LC, Barrucand L. Penicillin post-antibiotic effects on the biology of group A streptococci. J Antimicrob Chemother. 1995;36(3):475–82.

    Article  CAS  PubMed  Google Scholar 

  55. Cherkasov VL. [Use of bicillin for the prevention of recurrent erysipelas]. Sov Med. 1975(11):85–9.

  56. Wang JH, Liu YC, Cheng DL, et al. Role of benzathine penicillin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs. Clin Infect Dis. 1997;25(3):685–9.

    Article  CAS  PubMed  Google Scholar 

  57. Stember RH. Prevalence of skin test reactivity in patients with convincing, vague, and unacceptable histories of penicillin allergy. Allergy Asthma Proc. 2005;26(1):59–64.

    PubMed  Google Scholar 

  58. Solensky R. Hypersensitivity reactions to beta-lactam antibiotics. Clin Rev Allergy Immunol. 2003;24(3):201–20.

    Article  CAS  PubMed  Google Scholar 

  59. Solensky R. Drug desensitization. Immunol Allergy Clin North Am. 2004;24(3):425–43. vi.

    Article  PubMed  Google Scholar 

  60. Martin JM, Green M, Barbadora KA, Wald ER. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N Engl J Med. 2002;346(16):1200–6.

    Article  PubMed  Google Scholar 

  61. Tamayo J, Perez-Trallero E, Gomez-Garces JL, Alos JI. Resistance to macrolides, clindamycin and telithromycin in Streptococcus pyogenes isolated in Spain during 2004. J Antimicrob Chemother. 2005;56(4):780–2.

    Article  CAS  PubMed  Google Scholar 

  62. Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother. 2003;51(6):1339–50.

    Article  CAS  PubMed  Google Scholar 

  63. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med. 2002;136(11):834–44.

    Article  PubMed  Google Scholar 

  64. Kaplan EL, Johnson DR, Del Rosario MC, Horn DL. Susceptibility of group A beta-hemolytic streptococci to thirteen antibiotics: examination of 301 strains isolated in the United States between 1994 and 1997. Pediatr Infect Dis J. 1999;18(12):1069–72.

    Article  CAS  PubMed  Google Scholar 

  65. Shenoy RK, Kumaraswami V, Suma TK, et al. A double-blind, placebo-controlled study of the efficacy of oral penicillin, diethylcarbamazine or local treatment of the affected limb in preventing acute adenolymphangitis in lymphoedema caused by brugian filariasis. Ann Trop Med Parasitol. 1999;93(4):367–77.

    Article  CAS  PubMed  Google Scholar 

  66. Szuba A, Rockson SG. Lymphedema: classification, diagnosis and therapy. Vasc Med. 1998;3(2):145–56.

    Article  CAS  PubMed  Google Scholar 

  67. Didem K, Ufuk YS, Serdar S, Zumre A. The comparison of two different physiotherapy methods in treatment of lymphedema after breast surgery. Breast Cancer Res Treat. 2005;93(1):49–54.

    Article  PubMed  Google Scholar 

  68. Gloviczki P. Principles of surgical treatment of chronic lymphoedema. Int Angiol. 1999;18(1):42–6.

    CAS  PubMed  Google Scholar 

  69. Kim DI, Huh SH, Hwang JH, Joh JH. Excisional surgery for chronic advanced lymphedema. Surg Today. 2004;34(2):134–7.

    Article  PubMed  Google Scholar 

  70. Olszewski WL. The treatment of lymphedema of the extremities with microsurgical lympho-venous anastomoses. Int Angiol. 1988;7(4):312–21.

    CAS  PubMed  Google Scholar 

  71. Granzow JW, Soderberg JM, Kaji AH, Dauphine C. Review of current surgical treatments for lymphedema. Ann Surg Oncol. 2014;21(4):1195–201.

    Article  PubMed  Google Scholar 

  72. Young JR, Dewolfe VG. Recurrent lymphangitis of the leg associated with dermatophytosis. Report of 25 consecutive cases. Cleve Clin Q. 1960;27:19–24.

    Article  CAS  PubMed  Google Scholar 

  73. Haustein UF, Biella U, Tausch I, Knoll H. Treatment of chronic recurrent erysipelas with streptococcal vaccine. Hautarzt. 1989;40(4):215–21.

    CAS  PubMed  Google Scholar 

  74. Massell BF, Honikman LH, Amezcua J. Rheumatic fever following streptococcal vaccination. Report of three cases. JAMA. 1969;207(6):1115–9.

    Article  CAS  PubMed  Google Scholar 

  75. Mason JM, Thomas KS, Crook AM, et al. Prophylactic antibiotics to prevent cellulitis of the leg: economic analysis of the PATCH I & II trials. PLoS One. 2014;9(2):e82694.

    Article  PubMed Central  PubMed  Google Scholar 

  76. McArthur JD, Walker MJ. Domains of group A streptococcal M protein that confer resistance to phagocytosis, opsonization and protection: implications for vaccine development. Mol Microbiol. 2006;59(1):1–4.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Maciej Piotr Chlebicki and Choon Chiat Oh declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Singapore General Hospital, The Academia, 20 College Road, Singapore, 169856, Singapore

    Maciej Piotr Chlebicki

  2. Department of Dermatology, Singapore General Hospital, Singapore, Singapore

    Choon Chiat Oh

Authors
  1. Maciej Piotr Chlebicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Choon Chiat Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maciej Piotr Chlebicki.

Additional information

This article is part of the Topical Collection on Skin, Soft Tissue, Bone and Joint Infectious Diseases

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chlebicki, M.P., Oh, C.C. Recurrent Cellulitis: Risk Factors, Etiology, Pathogenesis and Treatment. Curr Infect Dis Rep 16, 422 (2014). https://doi.org/10.1007/s11908-014-0422-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11908-014-0422-0

Keywords

Search

Navigation